Analyst Predicts 16-Year Highs for Churning Drug Stock

One upbeat analyst is calling SRPT a key small- to mid-cap stock pick for 2018

Dec 27, 2017 at 9:49 AM
facebook twitter linkedin

Oppenheimer analyst Hartaj Singh weighed in bullishly today on Sarepta Therapeutics Inc (NASDAQ:SRPT), calling the biopharmaceutical stock "a key SMID-cap pick in our coverage universe." In a note to clients, Singh said, "We do not see any meaningful competition to SRPT’s [Duchenne muscular dystrophy] franchise for another 3-5 years," and reiterated both his "outperform" rating and a $76 price target on the shares.

It's been a blowout year for Sarepta stock, with the drugmaker's shares more than doubling in value over the course of 2017. SRPT has been consolidating some gains just below $57 since early November, but support from its rising 50-day moving average remains firmly intact. Out of the gate this morning, the security isn't showing any immediate signs of breaking out above its short-term ceiling; SRPT is just fractionally higher at $56.70.

Singh's price target, meanwhile, stands about 35% north of current levels, and in territory the stock hasn't touched since January 2002. It's a somewhat loftier target than the consensus, as SRPT's average 12-month price target checks in at $69.47.

However, bullish analyst ratings are nothing new for the stock. Among the 15 brokerage firms tracking SRPT, no fewer than 14 call it a "buy" or "strong buy," with just a single "hold" rounding out the ratings.

Sarepta Therapeutics has yet to win over the shorts, though. Short interest rose by 29.2% over the past two reporting periods, and now accounts for 23.5% of the stock's float. At SRPT's average daily trading volume, it would take 8.4 days for all of these shorted shares to be covered.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners